drug
gemcitabine
Phase 1updated 3mo agoby Continuity Biosciences LLC
Phase 1community read0 votes
🐶 often sniffed alongside
top 8- tagApproval6 co-mentions · 3 sources
- drugGEMCITABINE HYDROCHLORIDE3 co-mentions · 3 sources
- tagOncology3 co-mentions · 1 sources
- drugpaclitaxel1 co-mentions · 1 sources
- drugSOR-0071 co-mentions · 1 sources
- drugpaclitaxel albumin bound1 co-mentions · 1 sources
- drugAG [gemcitabine + nab-paclitaxel]1 co-mentions · 1 sources
- companyTianjin Medical University Cancer Institute and Hospital1 co-mentions · 1 sources
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying gemcitabine
- phase2A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
- phase2ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
- phase3Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- phase2Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
- phase3Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- phase2A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
- phase3A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- phase3An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
News(6)
- Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ RhapsidoProcessa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.fiercebiotech · 22d ago
- An ADC specialist sinks on safety concerns for blood cancer drugShares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”biopharma_dive · 2mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 3mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 3mo ago
- Dr Pant on the Mechanism of Action of Daraxonrasib in PDACShubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.onclive · 3mo ago
- Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic CancerDeirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.onclive · 3mo ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that